You are here

Articles

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

published: 5 May 2016

European LeukemiaNet Recommendations for the Management of CML

published: 15 April 2016

Mtss1 is a critical epigenetically regulated tumor suppressor in CML

published: 6 April 2016

Dasatinib Commonly Induces Lymphocytosis in CML Patients

published: 31 March 2016

TGF-alpha, IL-6 Levels Predict Responses and Outcomes in CML

published: 24 March 2016

TKIs in CML Linked With Vascular Events

published: 20 February 2016

MTSS1 Protein May Act As Tumor Suppressor, Downregulated in CML

published: 20 February 2016

Cell marker found for leukemia-initiating capacity in chronic myelogenous leukemia

published: 18 February 2016

At 5 Years, Nilotinib Offers Benefit Over Imatinib in CML

published: 11 February 2016

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

published: 6 January 2016

Government responds to Cancer Drugs Fund petition on blood cancer

published: 22 December 2015

International CML Foundation- November 2015 Newsletter

published: 21 December 2015

Prof. Steve O'brien's summary of ASH 2015

published: 17 December 2015

ASH Abstract: 137 Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort

published: 9 December 2015

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

published: 11 November 2015

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

published: 11 November 2015

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

published: 7 November 2015

Musculoskeletal Pain - TKI Withdrawal Syndrome?

published: 5 November 2015

Effect of a proton pump inhibitor on the pharmacokinetics of imatinib

published: 13 October 2015

Cancer Drugs Fund

published: 7 October 2015